Endocrinologic and Psychologic Evaluation of 21-Hydroxylase Deficiency Carriers and Matched Normal Subjects: Evidence for Physical and/or Psychologic Vulnerability to Stress

Journal of Clinical Endocrinology and Metabolism

Volumn 89, Issue 5, 2004, Pages 2228-2236

  Charmandari, Evangelia ^a   Merke, Deborah P ^a,b   Negro, Paulo J ^c   Keil, Margaret F ^a   Martinez, Pedro E ^c   Haim, Adam ^c   Gold, Philip W ^c   Chrousos, George P ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; CORTICOTROPIN; HYDROCORTISONE; HYDROXYPROGESTERONE; STEROID 21 MONOOXYGENASE;

ADULT; ANXIETY; ARTICLE; BECK DEPRESSION INVENTORY; CHRONIC DISEASE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONGENITAL ADRENAL HYPERPLASIA; CONTROLLED STUDY; DEPRESSION; DISEASE PREDISPOSITION; ENDOCRINE FUNCTION; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS; LINEAR REGRESSION ANALYSIS; MALE; MOOD; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; PSYCHOMETRY; SHEEP; STEROID 21 MONOOXYGENASE DEFICIENCY; STRESS; SYMPTOMATOLOGY;

ADRENAL HYPERPLASIA, CONGENITAL; ADULT; CASE-CONTROL STUDIES; CHRONIC DISEASE; DISEASE SUSCEPTIBILITY; ENDOCRINE GLANDS; ENDOCRINE SYSTEM DISEASES; FEMALE; HETEROZYGOTE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PSYCHOLOGICAL TESTS; PSYCHOMETRICS; STRESS;

OVIS; OVIS ARIES;

EID: 2442585260     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-031322     Document Type: Article

References (46)

1. Speiser PW, White PC 2003 Congenital adrenal hyperplasia. N Engl J Med 349:776-788
2. White PC, Speiser PW 2000 Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 21:245-291
3. Merke DP, Bornstein SR, Avila NA, Chrousos GP 2002 NIH conference. Future directions in the study and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Ann Intern Med 136:320-334
4. White PC, New MI 1992 Genetic basis of endocrine disease 2: congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 74:6-11
5. New MI, Lorenzen F, Lerner AJ, Kohn B, Oberfield SE, Pollack MS, Dupont B, Stoner E, Levy DJ, Pang S, Levine LS 1983 Genotyping steroid 21-hydroxylase deficiency: hormonal reference data. J Clin Endocrinol Metab 57:320-326
6. Speiser PW, Dupont B, Rubinstein P, Piazza A, Kastelan A, New MI 1985 High frequency of nonclassical steroid 21-hydroxylase deficiency. Am J Hum Genet 37:650-667
7. Gutai JP, Kowarski AA, Migeon CJ 1977 The detection of the heterozygous carrier for congenital virilizing adrenal hyperplasia. J Pediatr 90:924-929
8. Krensky AM, Bongiovanni AM, Marino J, Parks J, Tenore A 1977 Identification of heterozygote carriers of congenital adrenal hyperplasia by radioimmunoassay of serum 17-OH progesterone. J Pediatr 90:930-933
9. Handelsman DJ, Howe CJ, Conway AJ, Turtle JR 1983 Heterozygote detection in congenital adrenal hyperplasia. Clin Chem 29:48-50
10. Peter M, Sippell WG, Lorenzen F, Willig RP, Westphal E, Grosse-Wilde H 1990 Improved test to identify heterozygotes for congenital adrenal hyperplasia without index case examination. Lancet 335:1296-1299
11. Chrousos GP 1995 The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 332:1351-1362
12. Chrousos GP 1998 Stressors, stress, and neuroendocrine integration of the adaptive response. The 1997 Hans Selye Memorial Lecture. Ann NY Acad Sci 851:311-335.
13. Gold PW, Chrousos GP 2002 Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs. low CRH/NE states. Mol Psychiatry 7:254-275
14. Owens MJ, Nemeroff CB 1991 Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev 43:425-473
15. Habib KE, Gold PW, Chrousos GP 2001 Neuroendocrinology of stress. Endocrinol Metab Clin North Am 30:695-728; vii-viii
16. Bornstein S, Bottner A, Chrousos G 1999 Knocking out the stress response. Mol Psychiatry 4:403-407
17. Elenkov IJ, Webster EL, Torpy DJ, Chrousos GP 1999 Stress, corticotropin-releasing hormone, glucocorticoids, and the immune/inflammatory response: acute and chronic effects. Ann NY Acad Sci 876:1-11; discussion 11-13
18. Makino S, Hashimoto K, Gold PW 2002 Multiple feedback mechanisms activating corticotropin-releasing hormone system in the brain during stress. Pharmacol Biochem Behav 73:147-158
19. Habib KE, Weld KP, Rice KC, Pushkas J, Champoux M, Listwak S, Webster EL, Atkinson AJ, Schulkin J, Contoreggi C, Chrousos GP, McCann SM, Suomi SJ, Higley JD, Gold PW 2000 Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc Natl Acad Sci USA 97:6079-6084
20. Belanoff JK, Flores BH, Kalezhan M, Sund B, Schatzberg AF 2001 Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol 21:516-521
21. Heim C, Nemeroff CB 1999 The impact of early adverse experiences on brain systems involved in the pathophysiology of anxiety and affective disorders. Biol Psychiatry 46:1509-1522
22. Spielberger CD 1983 Manual for the state-trait anxiety inventory (STAI). Palo Alto, CA: Consulting Psychologists Press
23. Beck AT, Blamesderfer A 1974 Assessment of depression: the depression inventory. In: Pichot P, ed. Psychological measurements in psychopharmacology. Modern problems in pharmacotherapy. Vol 7. Basel, Paris: Karger
24. McNair D, Lorr M, Droppleman L 1971 Psychiatric Outpatient Mood Scale. Boston: Psychopharmacology Laboratory, Boston University, Medical Center
25. Derogatis LR 1977 SCL-90-R: administration, scoring and procedures manual II. Towson, MD: Clinical Psychometric Research
26. Cloninger CF, Przybeck TR, Svrakic DM 1991 The Tridimensional Personality Questionnaire: W. S. Normative Data. Psychol Rep 69:1047-1057
27. Altemus M, Pigott T, Kalogeras KT, Demitrack M, Dubbert B, Murphy DL, Gold PW 1992 Abnormalities in the regulation of vasopressin and corticotropin releasing factor secretion in obsessive-compulsive disorder. Arch Gen Psychiatry 49:9-20
28. Altemus M, Swedo SE, Leonard HL, Richter D, Rubinow DR, Potter WZ, Rapoport JL 1994 Changes in cerebrospinal fluid neurochemistry during treatment of obsessive-compulsive disorder with clomipramine. Arch Gen Psychiatry 51:794-803
29. Schweizer EE, Swenson CM, Winokur A, Rickels K, Maislin G 1986 The dexamethasone suppression test in generalised anxiety disorder. Br J Psychiatry 149:320-322
30. Schreiber W, Lauer CJ, Krumrey K, Holsboer F, Krieg JC 1996 Dysregulation of the hypothalamic-pituitary-adrenocortical system in panic disorder. Neuropsychopharmacology 15:7-15
31. Dunn AJ, Berridge CW 1990 Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Res Brain Res Rev 15:71-100
32. Heinrichs SC, Menzaghi F, Merlo Pich E, Britton KT, Koob GF 1995 The role of CRF in behavioral aspects of stress. Ann NY Acad Sci 771:92-104
33. Skutella T, Montkowski A, Stohr T, Probst JC, Landgraf R, Holsboer F, Jirikowski GF 1994 Corticotropin-releasing hormone (CRH) antisense oligodeoxynucleotide treatment attenuates social defeat-induced anxiety in rats. Cell Mol Neurobiol 14:579-588
34. Arborelius L, Owens MJ, Flotsky PM, Nemeroff CB 1999 The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 160:1-12
35. Liang KC, Lee EH 1988 Intra-amygdala injections of corticotropin releasing factor facilitate inhibitory avoidance learning and reduce exploratory behavior in rats. Psychopharmacology (Berl) 96:232-236
36. Bakshi VP, Smith-Roe S, Newman SM, Grigoriadis DE, Kalin NH 2002 Reduction of stress-induced behavior by antagonism of corticotropin-releasing hormone 2 (CRH2) receptors in lateral septum or CRH1 receptors in amygdala. J Neurosci 22:2926-2935
37. Deak T, Nguyen KT, Ehrlich AL, Watkins LR, Spencer RL, Maier SF, Licinio J, Wong ML, Chrousos GP, Webster E, Gold PW 1999 The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress. Endocrinology 140:79-86
38. Plotsky PM, Meaney MJ 1993 Early, postnatal experience alters hypothalamic corticotropin-releasing factor (CRF) mRNA, median eminence CRF content and stress-induced release in adult rats. Brain Res Mol Brain Res 18:195-200
39. Ladd CO, Owens MJ, Nemeroff CB 1996 Persistent changes in corticotropin-releasing factor neuronal systems induced by maternal deprivation. Endocrinology 137:1212-1218
40. Ladd CO, Huot RL, Thrivikraman KV, Nemeroff CB, Meaney MJ, Plotsky PM 2000 Long-term behavioral and neuroendocrine adaptations to adverse early experience. Prog Brain Res 122:81-103
41. Liu D, Diorio J, Tannenbaum B, Caldji C, Francis D, Freedman A, Sharma S, Pearson D, Plotsky PM, Meaney MJ 1997 Maternal care, hippocampal glucocorticoid receptors, and hypothalamic-pituitary-adrenal responses to stress. Science 277:1659-1662
42. Caldji C, Tannenbaum B, Sharma S, Francis D, Plotsky PM, Meaney MJ 1998 Maternal care during infancy regulates the development of neural systems mediating the expression of fearfulness in the rat. Proc Natl Acad Sci USA 95:5335-5340
43. Suomi SJ 1991 Early stress and adult emotional reactivity in rhesus monkeys. Ciba Found Symp 156:171-183
44. Heim C, Newport DJ, Heit S, Graham YP, Wilcox M, Bonsall R, Miller AH, Nemeroff CB 2000 Pituitary-adrenal and autonomic responses to stress in women after sexual and physical abuse in childhood. JAMA 284: 592-597
45. De Bellis MD, Chrousos GP, Dorn LD, Burke L, Helmers Y, Kling MA, Trickett PK, Putnam FW 1994 Hypothalamic-pituitary-adrenal axis dysregulation in sexually abused girls. J Clin Endocrinol Metab 78: 249-255
46. Charmandari E, Kino T, Souvatzoglou E, Chrousos GP 2003 Pediatric stress-hormonal mediators and human development. Horm Res 59:161-179